📊 AMGN Key Takeaways
Is Amgen Inc. (AMGN) a Good Investment?
Amgen demonstrates exceptional fundamental strength with robust revenue growth of 10% YoY, exceptional profitability (21% net margin, 24.7% operating margin), and strong free cash flow generation of $8.1B. The company's operating performance is outstanding, evidenced by 88.5% YoY net income growth and ROE of 89.1%, indicating highly efficient capital deployment despite leverage headwinds.
Amgen shows solid fundamental momentum, with double-digit revenue growth, a sharp rebound in net income and EPS, and strong free cash flow generation. However, the balance sheet is heavily levered, interest coverage is only moderate, and ROE is flattered by a small equity base, which tempers the quality of the earnings recovery. Overall, the business appears fundamentally resilient, but financial risk keeps the profile balanced rather than clearly aggressive.
Why Buy Amgen Inc. Stock? AMGN Key Strengths
- Exceptional profitability: 21% net margin and 24.7% operating margin demonstrate pricing power and operational efficiency in biologics
- Strong cash generation: $10B operating cash flow and $8.1B free cash flow provide financial flexibility and capital return capacity
- Robust revenue growth: 10% YoY growth combined with 88.5% net income growth shows operational leverage and improving execution
- High return on equity: 89.1% ROE demonstrates superior capital efficiency despite high leverage, suggesting strong asset quality and earnings power
- Revenue grew 10.0% year over year, indicating continued top-line expansion
- Free cash flow of $8.10B and a 22.0% FCF margin support operational quality and financial flexibility
- Operating margin of 24.7% and net margin of 21.0% show strong earnings conversion despite a complex operating environment
AMGN Stock Risks: Amgen Inc. Investment Risks
- High leverage: 6.31x debt-to-equity ratio and $54.6B long-term debt creates financial risk, requiring sustained cash flow to service obligations
- Weak liquidity metrics: 1.14x current ratio and 0.90x quick ratio indicate tight short-term liquidity relative to current liabilities
- Thin interest coverage: 3.3x interest coverage is adequate but leaves limited margin for earnings deterioration or rate increases
- Biological products sector risk: Pipeline dependency and regulatory/patent cliff risks inherent to biopharmaceutical business model
- High leverage, with $54.60B of long-term debt and debt-to-equity of 6.31x, increases balance-sheet risk
- Interest coverage of 3.3x leaves limited cushion if earnings weaken or financing costs stay elevated
- ROE of 89.1% is likely distorted by the low equity base, making headline profitability look stronger than underlying capital strength
Key Metrics to Watch
- Free cash flow sustainability and ability to reduce debt-to-equity below 5.0x
- Revenue growth trajectory and product pipeline clinical/commercial success
- Operating margin maintenance as revenue scales and competitive pressures evolve
- Quarterly cash flow trends and capital allocation decisions (debt reduction vs. shareholder returns)
- Debt reduction and interest coverage improvement
- Sustained free cash flow and operating margin performance
Amgen Inc. (AMGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 22.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
AMGN Profit Margin, ROE & Profitability Analysis
AMGN vs Healthcare Sector: How Amgen Inc. Compares
How Amgen Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amgen Inc. Stock Overvalued? AMGN Valuation Analysis 2026
Based on fundamental analysis, Amgen Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amgen Inc. Balance Sheet: AMGN Debt, Cash & Liquidity
AMGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amgen Inc.'s revenue has grown significantly by 41% over the 5-year period, indicating strong business expansion. The most recent EPS of $12.49 reflects profitable operations.
AMGN Revenue Growth, EPS Growth & YoY Performance
AMGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.5B | $2.8B | $5.22 |
| Q2 2025 | $8.4B | $633.0M | $1.17 |
| Q1 2025 | $7.4B | -$113.0M | $-0.21 |
| Q3 2024 | $6.9B | -$113.0M | $3.22 |
| Q2 2024 | $7.0B | -$113.0M | $1.17 |
| Q1 2024 | $6.1B | -$113.0M | $-0.21 |
| Q3 2023 | $6.7B | $1.3B | $3.22 |
| Q2 2023 | $6.6B | $1.3B | $2.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amgen Inc. Dividends, Buybacks & Capital Allocation
AMGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amgen Inc. (CIK: 0000318154)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMGN
What is the AI rating for AMGN?
Amgen Inc. (AMGN) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (HOLD) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMGN's key strengths?
Claude: Exceptional profitability: 21% net margin and 24.7% operating margin demonstrate pricing power and operational efficiency in biologics. Strong cash generation: $10B operating cash flow and $8.1B free cash flow provide financial flexibility and capital return capacity. ChatGPT: Revenue grew 10.0% year over year, indicating continued top-line expansion. Free cash flow of $8.10B and a 22.0% FCF margin support operational quality and financial flexibility.
What are the risks of investing in AMGN?
Claude: High leverage: 6.31x debt-to-equity ratio and $54.6B long-term debt creates financial risk, requiring sustained cash flow to service obligations. Weak liquidity metrics: 1.14x current ratio and 0.90x quick ratio indicate tight short-term liquidity relative to current liabilities. ChatGPT: High leverage, with $54.60B of long-term debt and debt-to-equity of 6.31x, increases balance-sheet risk. Interest coverage of 3.3x leaves limited cushion if earnings weaken or financing costs stay elevated.
What is AMGN's revenue and growth?
Amgen Inc. reported revenue of $36.8B.
Does AMGN pay dividends?
Amgen Inc. pays dividends, with $5,124.0M distributed to shareholders in the trailing twelve months.
Where can I find AMGN SEC filings?
Official SEC filings for Amgen Inc. (CIK: 0000318154) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMGN's EPS?
Amgen Inc. has a diluted EPS of $14.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Amgen Inc. has a BUY rating with 84% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is AMGN stock overvalued or undervalued?
Valuation metrics for AMGN: ROE of 89.1% (sector avg: 15%), net margin of 21.0% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy AMGN stock in 2026?
Our dual AI analysis gives Amgen Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is AMGN's free cash flow?
Amgen Inc.'s operating cash flow is $10.0B, with capital expenditures of $1.9B. FCF margin is 22.0%.
How does AMGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 21.0% (avg: 12%), ROE 89.1% (avg: 15%), current ratio 1.14 (avg: 2).
Is Amgen Inc. carrying too much debt?
AMGN has a debt-to-equity ratio of 6.31x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.14 suggests adequate short-term liquidity.
Why is AMGN's return on equity (ROE) so high?
Amgen Inc. has a return on equity of 89.1%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 21.0% net margin.